Affimed N.V. announced the appointments of Dr. Annalisa Jenkins and Mr. Harry Welten to its Supervisory Board. Both these appointments were approved during the Annual General Meeting of Shareholders which took place on August 4, 2020. Dr. Jenkins, with more than 25 years of global pharmaceutical experience. Dr. Jenkins served as the Chief Executive Officer of PlaqueTec Ltd. and Dimension Therapeutics. Prior leadership roles held by Dr. Jenkins include Executive Vice President, Global Research and Development­ at Merck Serono Pharmaceuticals as well as several leadership positions at Bristol-Myers Squibb. Mr. Welten brings significant financial and U.S. market expertise to Affimed. He is chairman and member of the board of directors of several biotechnology companies in Switzerland, Germany and the U.S. Mr. Welten served as Chief Financial Officer of both public as well as venture capital financed biotech companies. Mr. Welten has served in senior roles at UBS in Switzerland and New York for the first 15 years of his career.